Joel V. Chua, MD

Infectious Disease Fellowship, University of Maryland Medical Center, 2008-2010

Internal Medicine Residency, University of Connecticut Health Center, 2005-2008

Internal Medicine Residency, University of the Philippines - Philippine General Hospital, 2002-2004

Doctor of Medicine (M.D.), cum laude, University of the Philippines College of Medicine, 1996-2001

Bachelor of Science (B.S.), Major in Biology, magna cum laude, University of the Philippines Manila, 1992-1996 

Hepatitis B therapeutics; Hepatitis C therapeutics; and HIV-1 vaccine

1. Chua JV, Kottilil S.  Are we nearing the end in the fight against hepatitis C? Expert Review of Gastroenterology and Hepatology, 2017. doi:10.1080/17474124.2017.1309287. Accepted 17 March 2017. EPub.
2. Chua JV, Kottilil S. Sofosbuvir and velpatasvir: A stellar option for patients with decompensated hepatitis C (HCV) cirrhosis.  Ann Trans Med. 2016 Oct; 4 (Suppl 1):S8.
3. Chen WH, Winokur PL, Chua JV, Kotloff KL; Pandemic H1N1 Vaccine Adult Study Group. Phase 2 assessment of the safety and immunogenicity of two inactivated pandemic monovalent H1N1 vaccines in adults as a component of the U.S. pandemic preparedness plan in 2009. Vaccine. 2012; 30: 4240-4248 (Epub 23 Apr 2012).
4. Jackson LA, Chen WH, Stapleton JT, Dekker CL, Wald A, Brady RC, Edupuganti S,  Winokur P, Mulligan, Keyserling HL, Kotloff KL, Rouphael N, Noah DL, Hill H, Chua JV, Wolff MC. Immunogenicity and safety of varying dosages of a monovalent 2009 H1N1 influenza vaccine given with and without AS03 adjuvant system in healthy adults and older persons. J Infect Dis. 2012 Sep; 206(6):811-820 (Epub 10 Jul 2012).